109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
用于口腔癌诊疗管理的纳米材料：成像、生物传感、靶向递送及多模式协同治疗的进展
Authors Zhu X, Chen J , Zhao J , Zhang Z , Wang C
Received 15 August 2025
Accepted for publication 29 October 2025
Published 13 November 2025 Volume 2025:20 Pages 13689—13719
DOI https://doi.org/10.2147/IJN.S560993
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Lijie Grace Zhang
Xingcheng Zhu,1,* Junhao Chen,2,* Junxian Zhao,3,* Zhongsong Zhang,4 Chengjie Wang5
1Department of Clinical Laboratory, The Second People’s Hospital of Qujing City, Qujing, Yunnan, People’s Republic of China; 2Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People’s Republic of China; 3Department of Urology, 920th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Kunming, Yunnan, People’s Republic of China; 4School of Clinical Medicine, Chengdu Medical College, Chengdu, 610550, People’s Republic of China; 5School of Stomatology, Xinjiang Second Medical College, Karamay, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhongsong Zhang; Chengjie Wang, Email zzscmc1122@163.com; wcj15971579@163.com
Abstract: Oral squamous cell carcinoma (OSCC), which accounts for over 90% of oral cancer cases, is often diagnosed at advanced stages, resulting in a five-year survival rate of less than 40%. Current diagnostic methods, such as visual examination, biopsy, and conventional imaging, have limitations in sensitivity, specificity, and invasiveness. Conventional treatments like surgery, radiotherapy, and chemotherapy also pose significant challenges due to functional loss, toxicity, and poor patient compliance. These issues have prompted the exploration of nanomaterials as promising theranostic tools. Due to their tunable properties, high surface area, and biocompatibility, nanomaterials offer innovative solutions for OSCC diagnosis and therapy. They enable enhanced imaging resolution, ultrasensitive biomarker detection, and targeted, stimuli-responsive drug delivery systems that improve therapeutic outcomes while minimizing side effects. Additionally, nanoplatforms can combine chemotherapy, photothermal therapy (PTT), photodynamic therapy (PDT), gene therapy, and immunotherapy to address challenges like multidrug resistance and tumor hypoxia. This review highlights the novel role of nanomaterials in OSCC, focusing on their use in diagnostic enhancement, targeted therapies, and multimodal treatment strategies. Finally, we discuss the challenges of clinical translation, including synthesis scalability, regulatory standards, and long-term safety, while suggesting future directions, such as biodegradable nanomaterials, AI-based personalized treatment platforms, and improved clinical trial designs.
Keywords: oral cancer, nanomedicine, drug delivery, combination therapy, precision medicine
1Department of Clinical Laboratory, The Second People’s Hospital of Qujing City, Qujing, Yunnan, People’s Republic of China; 2Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People’s Republic of China; 3Department of Urology, 920th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Kunming, Yunnan, People’s Republic of China; 4School of Clinical Medicine, Chengdu Medical College, Chengdu, 610550, People’s Republic of China; 5School of Stomatology, Xinjiang Second Medical College, Karamay, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhongsong Zhang; Chengjie Wang, Email zzscmc1122@163.com; wcj15971579@163.com
Abstract: Oral squamous cell carcinoma (OSCC), which accounts for over 90% of oral cancer cases, is often diagnosed at advanced stages, resulting in a five-year survival rate of less than 40%. Current diagnostic methods, such as visual examination, biopsy, and conventional imaging, have limitations in sensitivity, specificity, and invasiveness. Conventional treatments like surgery, radiotherapy, and chemotherapy also pose significant challenges due to functional loss, toxicity, and poor patient compliance. These issues have prompted the exploration of nanomaterials as promising theranostic tools. Due to their tunable properties, high surface area, and biocompatibility, nanomaterials offer innovative solutions for OSCC diagnosis and therapy. They enable enhanced imaging resolution, ultrasensitive biomarker detection, and targeted, stimuli-responsive drug delivery systems that improve therapeutic outcomes while minimizing side effects. Additionally, nanoplatforms can combine chemotherapy, photothermal therapy (PTT), photodynamic therapy (PDT), gene therapy, and immunotherapy to address challenges like multidrug resistance and tumor hypoxia. This review highlights the novel role of nanomaterials in OSCC, focusing on their use in diagnostic enhancement, targeted therapies, and multimodal treatment strategies. Finally, we discuss the challenges of clinical translation, including synthesis scalability, regulatory standards, and long-term safety, while suggesting future directions, such as biodegradable nanomaterials, AI-based personalized treatment platforms, and improved clinical trial designs.
Keywords: oral cancer, nanomedicine, drug delivery, combination therapy, precision medicine